The recent decision by the U.S. Food and Drug Administration (FDA) to consider expanding the employ of leucovorin calcium tablets – a drug traditionally used in cancer treatment – to include patients with cerebral folate deficiency (CFD) and autistic features has raised concerns about potential disruptions to supply, particularly as the drug is already facing shortages. This development, announced on September 22, 2025, comes as healthcare professionals and patients grapple with the implications of repurposing a vital cancer medication for a broader patient population. The core question facing oncologists and patients alike is: will expanding the indications for leucovorin impact its availability for those who rely on it for cancer care?
Leucovorin has long been a critical component in chemotherapy regimens, often used to counteract the side effects of methotrexate and 5-fluorouracil. It works by helping cells to use folate, a B vitamin essential for growth and development. The FDA’s action stems from a systematic analysis of literature spanning 2009-2024, including case reports and mechanistic data, which suggests leucovorin calcium can benefit individuals with CFD. Individuals with CFD experience developmental delays and often exhibit autistic features, including challenges with social communication, sensory processing and repetitive behaviors, as well as seizures and motor coordination issues. “We have witnessed a tragic four-fold increase in autism over two decades,” said FDA Commissioner Marty Makary, M.D., M.P.H. “Children are suffering and deserve access to potential treatments that have shown promise. We are using gold standard science and common sense to deliver for the American people.”
Understanding the Leucovorin Shortage
The potential for increased demand due to the fresh indication arrives at a time when leucovorin is already experiencing supply constraints. While the FDA has not officially declared a shortage, reports from pharmacies and healthcare providers indicate difficulties in consistently obtaining the necessary dosages. These challenges are compounded by manufacturing issues and increased demand, factors that have historically led to drug shortages. The American Society of Health-System Pharmacists (ASHP) maintains a comprehensive list of drug shortages, and while leucovorin isn’t currently listed as critically short, the situation is being closely monitored. ASHP’s Drug Shortages provides up-to-date information on medication availability.
How the FDA is Approaching the Issue
The FDA is actively working with GSK, the manufacturer of Wellcovorin (leucovorin calcium), to facilitate the relabeling process and ensure a smooth transition. George Tidmarsh, M.D., Ph.D., Director of the FDA’s Center for Drug Evaluation and Research, emphasized the agency’s commitment to repurposing drugs for chronic diseases. “The FDA is collaborating with GSK to broaden the existing Wellcovorin label,” Tidmarsh stated. The agency’s approach involves incorporating essential scientific information for the safe and effective use of leucovorin in both adult and pediatric patients with CFD. This process is intended to minimize disruption to the existing supply chain while expanding access to a potentially beneficial treatment for individuals with CFD.
Impact on Cancer Patients: A Complex Equation
The impact on cancer patients is a primary concern. Oncologists are carefully assessing the potential implications and developing contingency plans. While the oral form of leucovorin is the one receiving the expanded indication, the injectable form remains crucial for many cancer treatments. The fear is that increased overall demand – even if primarily for the oral formulation – could strain manufacturing capacity and exacerbate existing shortages of the injectable form. This could lead to delays in chemotherapy treatments or the need to substitute alternative medications, potentially impacting patient outcomes.
The FDA acknowledges this concern and is working to mitigate potential disruptions. The agency is exploring options to incentivize increased production of leucovorin and ensure that cancer patients continue to have access to this essential medication. However, the complexities of pharmaceutical manufacturing and supply chains mean that You’ll see no easy solutions. The situation highlights the broader challenges of drug shortages and the need for proactive measures to prevent them.
What is Cerebral Folate Deficiency?
Cerebral folate deficiency (CFD) is a rare genetic neurological disorder that affects the brain’s ability to utilize folate. This deficiency can lead to a range of neurological symptoms, including developmental delays, movement disorders, and seizures. The FDA’s decision to consider leucovorin for CFD is based on evidence suggesting that the drug can help improve folate transport into the brain, potentially alleviating these symptoms. The connection between CFD and autism spectrum disorder is increasingly recognized, with many individuals with CFD exhibiting autistic features.
Stakeholders and Next Steps
The key stakeholders in this situation include cancer patients, individuals with CFD and their families, oncologists, neurologists, pharmaceutical manufacturers (GSK), and the FDA. The FDA is expected to finalize the relabeling of Wellcovorin in the coming months, which will pave the way for broader access to leucovorin for patients with CFD. GSK has preliminarily agreed to collaborate with the FDA on this effort. Healthcare providers are advised to stay informed about the latest developments and to proactively manage potential supply challenges. Patients are encouraged to discuss any concerns with their doctors.
The FDA remains committed to finding and treating the root causes of autism, as Commissioner Makary emphasized. This decision regarding leucovorin represents a step towards exploring new treatment options for individuals with CFD and autism, but it also underscores the importance of careful planning and collaboration to ensure that all patients have access to the medications they need.
The next official update from the FDA regarding the relabeling of Wellcovorin is anticipated in early March 2026. Ongoing monitoring of leucovorin supply levels will be crucial in the coming months to assess the impact of the expanded indication.
Have thoughts on this developing story? Share your comments below, and please share this article with your network.
Worth a look
